United States
Print page content Print
Increase text size Decrease text size
Text Size

In this section

HRQoL

Dogs who responded to treatment demonstrated improved HRQoL

  • HRQoL was assessed via owner survey in the PALLADIA clinical field study, using parameters such as mobility, appetite, and activity level3
  • Health-related quality of life was significantly improved (P = 0.030) in dogs demonstrating an objective response to PALLADIA3

Health-related quality of life assessment form

  • The HRQoL questionnaire (Canine Cancer Treatment Survey) is designed for completion by the owners of pets receiving treatment for cancer. If this may be of assistance to you in clinical case management or as a component of clinical trials, we welcome you to utilize it. Click Here to access the form.

IMPORTANT SAFETY INFORMATION: During clinical studies, the most common adverse events associated with PALLADIA included: diarrhea, anorexia (including decreased appetite), lethargy, neutropenia, emesis, lameness, weight loss, musculoskeletal disorder, and blood in stool/GI bleed/hemorrhagic diarrhea. PALLADIA may cause vascular dysfunction, which can lead to edema and thromboembolism, including pulmonary thromboembolism. Serious and sometime fatal GI complications, including GI perforation, have occurred rarely in dogs treated with PALLADIA. If GI ulceration is suspected stop drug administration and treat appropriately. Children should not come in contact with PALLADIA. In addition, all individuals, including children and pregnant women, should avoid direct contact with broken or partially dissolved PALLADIA tablets or biological waste from dogs treated with PALLADIA. To report a suspected adverse reaction call Zoetis at 1-888-963-8471. See full Prescribing Information

All trademarks are the property of Zoetis Inc., its affiliates and/or its licensors. Zoetis Inc. All rights reserved. August 2015. PAL-00040

REFERENCES:

3. London CA, Malpas PB, Wood-Follis SL, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009, 151(11):3856-3865.